Blueprint Medicines Corporation
BPMC
$88.48
-$0.03-0.03%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -49.96M | -56.27M | -50.00M | 89.14M | -110.92M |
| Total Depreciation and Amortization | 4.00M | 3.86M | 3.62M | 4.81M | 1.53M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 26.73M | 23.31M | 25.11M | -152.26M | 20.05M |
| Change in Net Operating Assets | -10.14M | 15.46M | -26.81M | -43.20M | 10.40M |
| Cash from Operations | -29.36M | -13.64M | -48.07M | -101.51M | -78.93M |
| Capital Expenditure | -932.00K | -25.00K | -2.57M | -1.10M | -4.67M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 34.64M | 29.98M | -185.72M | 78.24M | 83.44M |
| Cash from Investing | 33.71M | 29.95M | -188.29M | 77.13M | 78.77M |
| Total Debt Issued | 0.00 | 0.00 | 146.97M | -- | -35.00K |
| Total Debt Repaid | 0.00 | 0.00 | -172.00K | -369.00K | -44.00K |
| Issuance of Common Stock | 9.76M | 18.38M | 31.21M | 67.33M | 15.61M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 9.76M | 18.38M | 178.01M | 66.96M | 15.53M |
| Foreign Exchange rate Adjustments | -1.32M | 591.00K | -31.00K | -145.00K | 487.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 12.78M | 35.28M | -58.38M | 42.44M | 15.86M |